Andrew Left, Citron Research short seller who campaigned against Valeant, is...
For years, Andrew Left and his short-selling fund Citron Research were a swashbuckling presence on social media, accusing companies of fraud and misdeeds, and making stock bets that he was right. On...
View ArticleClik here to view.
Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout...
Bristol Myers Squibb has resumed recruitment for its lead radiopharmaceutical trial after an isotope shortage forced a pause earlier this year, chief medical officer Samit Hirawat said on the company’s...
View ArticlePfizer and BioNTech say GSK's Covid patent suit is 'groundless'
Pfizer and BioNTech have called GSK’s patent lawsuit “groundless,” accusing the British drugmaker of “improperly contorting” its claims to say their blockbuster Covid vaccine is covered by GSK patents....
View ArticleAmong pharma CEOs, the IRA now and the IRA later get very different reactions
Pharma has a message to investors about the results of the first round of drug price negotiations under the Inflation Reduction Act: It’s fine. Over the last two weeks, many of the drugmakers subject...
View ArticleCompounded weight loss drugs have resulted in misdosing, hospitalizations,...
The FDA on Friday alerted healthcare providers and the public that it’s seeing reports of unintended overdoses of the compounded version of self-injected weight loss drug semaglutide, which can be...
View ArticleMapping GLP-1 game plans; Q2 earnings highlights; J&J vets regroup at...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticlePfizer cuts 210 North Carolina workers after it officially discontinues...
Pfizer will end development on its experimental Duchenne muscular dystrophy gene therapy after a Phase 3 failure last month, and plans to eliminate roles at a North Carolina site that was working on...
View ArticleClik here to view.
Roivant's dealmaker lands $81M cash bonus following drug sale to Roche
One of the best pharma deals in recent history has now led to one of the industry’s biggest-ever executive paydays. Roivant awarded its top dealmaker Mayukh Sukhatme an $80.55 million cash bonus,...
View ArticleIndivior reaches $86M settlement over its alleged role in the opioid epidemic
Indivior will pay $86 million over five years as part of a settlement with 17 states over it’s alleged role in the opioid epidemic, New York Attorney General Letitia James announced last week....
View ArticleAstraZeneca and Daiichi Sankyo fail to win NICE recommendation for Enhertu,...
The United Kingdom’s drug pricing watchdog has officially declined to recommend AstraZeneca and Daiichi Sankyo’s Enhertu for HER2-low breast cancer in the UK, noting that the companies were “unwilling”...
View ArticleBessemer VC Morgan Cheatham shares how AI healthcare startups can win in a...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Among what seems like a gazillion startups using AI to solve administrative problems for healthcare...
View ArticleClik here to view.
Roche begins Phase 2 obesity trial for GLP-1/GIP agonist CT-388
Roche said it would step on the gas pedal to catch up to Novo Nordisk and Eli Lilly (plus many other hopefuls) in obesity. And it has. The Swiss pharma conglomerate has kicked off a Phase 2 trial of...
View ArticleKeytruda tops $7B quarterly sales for the first time
Merck’s Keytruda has a new line on its long list of accomplishments: topping $7 billion in quarterly sales for the first time. On Tuesday, the New Jersey drugmaker said the cancer drug’s quarterly...
View ArticleClik here to view.
Montara Therapeutics, co-founded by UCSF's Kevan Shokat, to develop new neuro...
A year after selling their first neuro startup to AbbVie, Kevan Shokat and the former PhD student he co-founded that company with are back with a new idea. Montara Therapeutics is starting small with...
View ArticleCelldex says barzolvolimab scores in Phase 2 test in chronic inducible urticaria
Celldex said its monoclonal antibody has shown encouraging efficacy in a mid-stage trial in patients with an inflammatory skin condition that features hives and swelling, setting the stage for...
View ArticleClik here to view.
Pfizer ups 2024 guidance by $1B after multiple rounds of cost cuts
Pfizer beat Wall Street’s expectations on revenue in the second quarter and raised its full-year revenue guidance by $1 billion, it said Tuesday morning. The large drugmaker pulled in $13.3 billion...
View ArticleBioNTech, Regeneron claim Phase 2 win for cancer vaccine, PD-1 combo
One of BioNTech’s first mRNA cancer vaccine candidates has cleared a key mid-stage trial, setting it up for a potential showdown with a closely-watched and more advanced program from Merck and Moderna....
View ArticleDay One's $175M PIPE; Pinetree raises $17M in Series A
Plus, news about LTZ Therapeutics and VBI Vaccines: Day One raises money, cuts drug: The Brisbane, CA-based biotech revealed a $175 million private placement, reeled in $8.2 million in sales from...
View ArticleClik here to view.
Imunon shares up over 150% as ovarian cancer treatment extends survival in...
Imunon shares skyrocketed Tuesday after the biotech reported positive survival data from a mid-stage trial of its IL-12 boosting immunotherapy on top of standard of care in ovarian cancer. The New...
View ArticleClik here to view.
Incyte drops four early-stage programs from its pipeline as part of strategic...
Incyte culled four early-stage assets and one mid-stage drug in a bid to stay competitive, particularly in the LAG-3 market. In its second-quarter earnings update, Incyte announced that it discontinued...
View Article